Betaxolol versus Carvedilol in Chronic Heart Failure (BETACAR Study)

Autor:	Steffen Böhler, Rudy Scheldewaert, Stéphane Saubadu, Hans-Reiner Figulla
Rok vydání:	2011
Předmět:	Inotrope medicine.medical_specialty Ejection fraction business.industry medicine.disease Highly selective Predictive value Betaxolol Surgery Heart failure Internal medicine Drug Discovery medicine Cardiology Left ventricular dilatation business Carvedilol medicine.drug
Zdroj:	Arzneimittelforschung. 49:311-317
ISSN:	1616-7066 0004-4172
DOI:	10.1055/s-0031-1300420
Popis:	The use of beta-blockers in heart failure for a long time was regarded as contra-indicated because of their negative inotropic effects. Nevertheless, there is growing evidence that beta-blockers slow down the progression of left ventricular dilatation that characterizes heart failure. In addition changes in left ventricular ejection fraction after several months of beta-blocker treatment appears to have predictive value for survival. This beneficial effect of beta-blockade in chronic heart failure needs to be assessed further. The presumed benefit of beta-blockade with betaxolol (CAS 63659-18-7), a highly selective beta-blocker with long duration of action in chronic heart failure (CHF) will be assessed in BETACAR, a comparative study versus carvedilol (CAS 72956-09-3). The design of this study is provided in this article.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a9122a94cb4a0ae5e89c43d6088f847a https://doi.org/10.1055/s-0031-1300420 Zobrazit plný text záznamu